A new type of cancer treatment has arrived that looks less like medicine and more like science fiction — except it's real, peer-reviewed, and already working in preclinical tests.
Researchers at Michigan State University, in collaboration with Henry Ford Health and Arizona State University, unveiled TriMag in March 2026: a biodegradable microrobot smaller than a human hair that combines three capabilities previously found only in separate, bulkier devices.
The first capability is precision magnetic guidance. Using external magnetic fields, TriMag can be steered through the body to an exact location — reaching tumours that would otherwise require invasive surgery to access. The second is real-time 3D tracking via magnetic particle imaging (MPI), which works without radiation and isn't obscured by organs or bones. Clinicians can watch where the robots are going as it happens.
The third — and most remarkable — is targeted magnetic hyperthermia. Once in position, the microrobots can be heated remotely to temperatures that destroy tumour cells while leaving surrounding healthy tissue largely unharmed. It's a kind of surgical precision without a surgeon.
The TriMag devices are fabricated using high-precision 3D printing, embedding biocompatible hydrogel with iron oxide and cobalt ferrite nanoparticles for their magnetic properties. After completing their task, they safely biodegrade inside the body.
Early preclinical results show significant tumour shrinkage, and the researchers believe the technology could extend beyond cancer treatment to less invasive eye procedures and complex brain surgeries. The team published their findings in March 2026 and is now working towards clinical trials.
'This is about reducing patient risk while increasing precision,' said one of the lead researchers. 'A device that navigates, tracks, and treats — all in one — changes what minimally invasive surgery could mean.'
